<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001677'>Coronary artery disease</z:hpo> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> carry concurrent risk for <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Mechanisms and clinical implications are discussed </plain></SENT>
</text></document>